DORADO-AC – Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Overview

This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. The treatment period for this trial is 14 weeks.

Full Title of Study: “A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo (Protocol DAR-312)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 2009

Interventions

  • Drug: Darusentan
    • Darusentan capsules administered orally once daily
  • Drug: Guanfacine
    • Guanfacine capsules administered orally once daily
  • Drug: Darusentan Placebo
    • Placebo to match darusentan administered orally once daily

Arms, Groups and Cohorts

  • Experimental: Darusentan
    • Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks
  • Active Comparator: Guanfacine
    • Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks
  • Placebo Comparator: Darusentan Placebo
    • Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry
    • Time Frame: Baseline to Week 14

Secondary Measures

  • Percentage of subjects reaching systolic blood pressure goal after 14 weeks of treatment
    • Time Frame: Week 14
  • Change from baseline in mean 24-hour systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM)
    • Time Frame: Baseline to Week 14
  • Change from baseline in estimated glomerular filtration rate (eGFR)
    • Time Frame: Baseline to Week 14

Participating in This Clinical Trial

SELECTED INCLUSION CRITERIA:

1. Subjects who are competent to provide written consent; 2. Aged 35 to 80 years; 3. Subjects with diabetes and/or chronic kidney disease must have an average sitting systolic blood pressure greater than or equal to 130 mmHg; 4. All other subjects must have an average sitting systolic blood pressure greater than or equal to 140 mmHg; 5. Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic; 6. Female subjects of non-childbearing potential (i.e., post-menopausal for at least 2 years or surgically sterile). SELECTED EXCLUSION CRITERIA:

1. Average sitting systolic and diastolic blood pressure greater than or equal to 180 mmHg and 110 mmHg, respectively; 2. Subjects treated with a central alpha-2 agonist and/or imidazoline receptor agonist; 3. Left ventricular dysfunction; 4. Serum ALT or AST greater than 2 times the Upper Limit of Normal; 5. Subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachycardia, recurrent ventricular tachycardia, or symptomatic bradycardia; 6. Implanted pacemakers or cardioverter defibrillator; 7. Symptomatic congestive heart failure requiring treatment; 8. Hemodynamically significant valvular heart disease; 9. Hemodialysis or peritoneal dialysis, or history of renal transplant; 10. Type I diabetes mellitus; 11. Diagnosis or recurrence of malignancy within the past 3 years; 12. Sleep apnea, unless a recent sleep study demonstrated arterial oxygenation saturation greater than or equal to 90%, treated or untreated; 13. Subjects who perform alternating shift or night work; 14. Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gilead Sciences
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.